LLY ELI LILLY Earnings and EPS analysis
- Stocks
- Healthcare
- NYSE: LLY
- Earnings
EPS in 2025 (TTM): $12.34
Last Report Period Date: Mar 31, 2025
Currently, LLY's trailing twelve months (TTM) EPS stands at $12.34, according to the most recent financial reports. In 2024, LLY reported a per-share earnings of $11.76, which represents an increase compared to the EPS of $5.82 recorded in 2023. LLY recorded an EPS of $3.07 for the quarterly period ending on Mar 31, 2025.
LLY earnings history
In 2024, ELI LILLY's EPS was $11.76, an increase of 102.1% from $5.82 in 2023. For the quarter ending Mar 31, 2025, the EPS was $3.07, reflecting a 23.3% increase compared to the same quarter a year earlier. The trailing twelve months (TTM) EPS as of March 2025 is $12.34. In 2023, the annual EPS was $5.82, showing a decrease of 16% compared to 2022.
LLY EPS growth
Over the past 12 months, ELI LILLY has recorded an earnings per share growth of 23.3% (YoY, quarterly). Over a three-year span, the company had an average EPS annual growth rate of 24.1% per year. Over the last five years, the company had an average annual EPS growth of 5.7%. When assessed over a ten-year period, LLY's average EPS annual growth was 18.1%.
LLY Earnings Waterfall
LLY Earnings vs Peers
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| MRK Merck & Co Inc | 11.15 | 4,728.6% | 9.4% | 12% |
| PFE Pfizer Inc | 16.9 | 273.7% | -28.7% | -13.2% |
| JNJ Johnson & Johnson | 17.13 | -57.9% | -9.7% | 0.4% |
| NVS Novartis AG | 17.98 | -17.2% | -17.9% | 2.9% |
| BMY Bristol Myers Squibb Co | 18.01 | -213.7% | N/A | N/A |
| AMGN Amgen Inc | 26.08 | -39.3% | -9.7% | -10.1% |
| AZN Astrazeneca plc | 29.02 | 18.2% | 284.3% | 34.3% |
| LLY ELI LILLY & Co | 59.78 | 102.1% | 24.1% | 5.7% |
| ABBV AbbVie Inc | 78.86 | -12.1% | -28.2% | -14.7% |
All data is based on quarterly TTM periods, unless otherwise specified.